Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 2,594 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,594 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $101.95, for a total value of $264,458.30. Following the transaction, the senior vice president owned 5,835 shares in the company, valued at approximately $594,878.25. This trade represents a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mirum Pharmaceuticals Stock Up 5.0%

Shares of NASDAQ:MIRM traded up $5.09 on Thursday, reaching $107.13. The company had a trading volume of 1,576,815 shares, compared to its average volume of 902,868. Mirum Pharmaceuticals, Inc. has a twelve month low of $47.89 and a twelve month high of $114.99. The stock has a 50-day moving average price of $98.29 and a 200 day moving average price of $91.88. The stock has a market capitalization of $6.53 billion, a P/E ratio of -7.87 and a beta of 0.50. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same period in the prior year, the company posted ($0.30) EPS. The business’s revenue was up 43.3% on a year-over-year basis. On average, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on MIRM shares. Citizens Jmp increased their price target on Mirum Pharmaceuticals from $140.00 to $146.00 and gave the company a “market outperform” rating in a report on Monday. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, June 8th. Finally, TD Cowen lifted their target price on shares of Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $139.80.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its holdings in shares of Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after buying an additional 880,505 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after acquiring an additional 50,720 shares during the last quarter. State Street Corp grew its stake in shares of Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after acquiring an additional 797,088 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Mirum Pharmaceuticals by 10.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after acquiring an additional 137,087 shares during the period. Finally, Wellington Management Group LLP increased its position in Mirum Pharmaceuticals by 56.6% during the fourth quarter. Wellington Management Group LLP now owns 1,237,830 shares of the company’s stock worth $97,776,000 after acquiring an additional 447,141 shares during the period.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.